Infirmary, Glasgow G4 OSF; and 2Gartnavel General Hospital, Glasgow G12 OYN SUMMARY A group of 54 patients with rheumatoid arthritis (31 fast, 23 slow acetylators) treated with sulphasalazine 3 g/day were studied retrospectively. At 24 weeks no difference in the efficacy of the drug could be shown between fast and slow acetylators. In a second prospective study 40 fast acetylators were allocated to 3 g/day and 20 slow acetylators to 1.5 g/day. At 24 weeks marked improvement was seen in the fast acetylators given high dose but not the slow acetylators given low dose. It was also noted in this study that the usual ratio of fast : slow acetylators was reversed, and there is some suggestion that fast acetylators may be predisposed to more severe rheumatoid arthritis. The toxicity pattern in a total of 149 patients (83 fast, 66 slow acetylators) was also studied. Significantly more slow acetylators stopped treatment because of nausea or vomiting, or both, but serious toxicity was not confined to either group. Acetylator phenotype therefore appears important in determining the incidence of nausea and/or vomiting associated with sulphasalazine therapy in patients with rheumatoid arthritis but has no effect on the occurrence of potentially serious toxicity or efficacy. Thus prior measurement of acetylator phenotype in patients with rheumatoid arthritis confers little practical benefit in their management.
Sulphasalazine has recently been resurrected as a second-line drug and has been shown to be effective in the treatment of rheumatoid arthritis. '-5 Sulphasalazine is the azo ester of sulphapyridine and 5-aminosalicylic acid (5-ASA). Only a small proportion (about 7%) is absorbed as sulphasalazine, and the remainder reaches the large intestine, where it is split by bacterial action at its azo bond into the constituent components. The 5-ASA remains largely within the large bowel and is excreted in the faeces unchanged. Only a small amount of 5-ASA reaches the systemic circulation, and in patients with ulcerative colitis peak serum levels reach only 1-4 4,g/ml (mg/1). Sulphapyridine, on the other hand, is almost totally absorbed and is eventually excreted in the urine either unchanged or after hepatic metabolism. The '2 14 In this paper we examine the effect of acetylator phenotype on the efficacy and toxicity of sulphasalazine in rheumatoid arthritis and examine whether allocation to different doses on the basis of acetylator phenotype improves the therapeutic ratio of the drug.
Patients and methods A summary of the various patient groups studied is given in Table 1 .
All patients studied suffered from classical or definite rheumatoid arthritis which remained clinically active despite optimum dosage of non-steroidal anti-inflammatory drugs (NSAIDs) and required the addition of a second-line agent in an attempt to control disease activity. As far as possible patients remained on the same NSAID at a constant dose throughout the study. No patients had known sulphonamide or salicylate sensitivity, and none had previously received sulphasalazine. Apart from two patients in study 4 (Table 1 ) no patients were taking or had ever taken corticosteroids for their rheumatoid arthritis, and none took other second-line drugs during the study or in the preceding three months.
All patients started on sulphasalazine (enteric coated) 0*5 glday, and the dose was increased by weekly increments of 0-5 g/day until the allocated dose was achieved or dose related toxicity was encountered. If after 18 weeks no benefit had been achieved the dose could be increased to a maximum of 4 g/day.
The four studies described were carried out in the same centre over a three-year period. 
zine (enteric coated) 1.5 g/day and fast acetylators to 3 g/day. The dose of 3 g/day was chosen as this is our standard clinical dose. 1-5 g/day for the slow acetylators was chosen arbitrarily, but it is the 'low dose' that we used previously in a study comparing doses.'5 Assessment of efficacy was carried out at 24
weeks.
TOXICITY STUDY
Acetylator phenotype was assessed in the 149 of the total 158 patients so far treated with sulphasalazine and described in Table 1 (Table 3) .
Clinical and laboratory parameters of inflammation and of toxicity are shown in Table 4 . At week 0 there were no significant differences between the two groups (Mann-Whitney U test, p> 0-05). Both slow and fast acetylators showed a statistically significant improvement in most inflammatory indices, and no significant differences could be shown between slow and fast acetylators for either the 24-week values or the degree of change (MannWhitney U test, p> 0.05).
PROSPECTIVE GROUP
Forty patients (66%) were fast acetylators and thus allocated to 3 g/day and 20 (33%) were slow acetylators and thus given 1-5 g/day. At 24 weeks 15 (75%) slow acetylators and 27 (68%) fast acetylators remained on treatment, again most achieved their allocated dose (Table 3) . One patient in the fast acetylator group stopped because of inefficacy. Unfortunately the slow acetylator/low dose group had a significantly lower erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) and higher haemoglobin (Mann-Whitney U test, p<0001) at the outset of therapy. Other parameters, however, were comparable (Mann-Whitney U test, p> 0.05). Table 3 Actual 24-week dose in various patient groups
Group
Allocated Actual daily dose at 24 weeks dose (g) (0-all day) (0-all day) (0-all day) IgA (g/l)
12-3 10-9 14-4 10-4**** (9-3-23-6) (4-7-18) (6-2-24-4) (4-3-20-9) 'gM (g/l)
C-reactive protein 25-5 13-9 40-5 10-7** (6-0-40-1) (6-0-62-1) (6-0-100) (6- group The data on efficacy are unfortunately less clear cut. Probably the simplest and, to those patients concerned, the most important measure of inefficacy is the proportion of patients who failed to complete the follow-up period because of continued severe arthritic symptoms (five (6%) fast acetylators, no slow acetylators). Such a difference between groups, however, does not achieve statistical significance, but more conclusive results might be obtained from a larger series. The retrospective data failed to show any advantages in terms of efficacy related to one particular acetylator phenotype. In the prospective study the fast acetylators/high dose patients showed improvement in more indices, and though slow acetylators/low dose patients had initially less active disease, the groups were indistinguishable in terms of disease activity at 24 weeks. This suggests that the higher dose might bring about a more favourable response even in fast acetylators, and the percentage improvement in ESR was greater in this group. Overall, these findings imply that any effect of acetylator phenotype on the efficacy of sulphasalazine is minor and is far outweighed by the effect of the dose. This relationship of dose to efficacy has been previously described. 15 Inclusion of retrospective data in these studies may invite criticism. However, data were only retrospective in as much as acetylator phenotype was assessed either during or after treatment, and all patients described were assessed by clinical and laboratory methods under clinical trial conditions in consecutive studies. A number of methods of assessing acetylator phenotype were used, but the literature indicates that correlation between these methods is excellent.16 17 It is also noteworthy that the previously reported UK ratio of slow:fast acetylators was reversed in this study. This may suggest an ethnic difference or a difference in the rheumatoid population. Previous work in Glasgow has shown no difference in the ratio of slow:fast acetylators either in normals or in rheumatoid patients21 when compared with earlier English studies.8 Thus the reversed ratio in our case may merely be accident or may reflect a preponderance of fast acetylators among patients with rheumatoid arthritis severe enough to require second-line drugs. The latter possibility is lent some credence by the fact that in study 3 
